<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512443</url>
  </required_header>
  <id_info>
    <org_study_id>Daflon25122019</org_study_id>
    <nct_id>NCT04512443</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome</brief_title>
  <official_title>Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Interregional Clinical Diagnostic Center, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Interregional Clinical Diagnostic Center, Russia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The article presents the results of a randomized, placebo-controlled study of the&#xD;
      conservative treatment with Daflon (Detralex) in female patients with Pelvic congestion&#xD;
      syndrome .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 28, 2019</start_date>
  <completion_date type="Actual">March 28, 2020</completion_date>
  <primary_completion_date type="Actual">March 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic Varicose Veins Questionnaire</measure>
    <time_frame>2 months</time_frame>
    <description>Assessment of quality of life according to the questionnaire before and after treatment</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">83</enrollment>
  <condition>Pelvic Congestion Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>42 women (treated with Daflon 1000 mg (study group))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>41 women (placebo (control group))</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daflon</intervention_name>
    <description>All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        women with Pelvic congestion syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢The presence of pelvic varicose veins verified by transvaginal and transabdominal duplex&#xD;
        ultrasound scanning&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe disease of the gastrointestinal tract or hematopoietic system&#xD;
&#xD;
          -  Terminal stage of cardiovascular, respiratory, renal or hepatic failure&#xD;
&#xD;
          -  Grade IV malignancy&#xD;
&#xD;
          -  Peripheral artery disease (PAD) of the lower extremities, any type of diabetes, or&#xD;
             mental disease.&#xD;
&#xD;
          -  Pregnant women at any gestational age, women who gave birth less than 12 months ago,&#xD;
             and breastfeeding mothers.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Akhmetzianov Rustem</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roman Bredikhin</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Interregional Clinical Diagnostic Center, Russia</investigator_affiliation>
    <investigator_full_name>Akhmetzianov Rustem</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

